Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avax up on lung cancer collaboration
Presbyterian Medical Center and Hospital of the University of Pennsylvania, both part of the University of Pennsylvania Health System, will be the exclusive partner and clinical sites for
Presbyterian Medical Center and Hospital of the University of Pennsylvania, both part of the University of Pennsylvania Health System, will be the exclusive partner and clinical sites for
IT&E has been awarded additional long-term contracts to continue its relationship with VaxGen, to provide additional services to support the production of 75 million doses of VaxGen’s anthrax
The phase I trial is the first ever to test a recombinant adeno-associated viral vector (rAAV)-based vaccine and is primarily designed to evaluate safety and tolerability of the
Approximately 40% of children suffer from allergies, the most frequently reported chronic condition in children, according to the Asthma and Allergy Foundation of America. PediaMed works to increase
The phase III clinical trial, named ARISE, is testing AGI-1067, AtheroGenics’ lead compound for the oral treatment of atherosclerosis, in leading cardiovascular research centers throughout the US, Canada,
In an amended complaint, filed on February 16, 2005, Tercica and Genentech challenged Insmed’s right to commercialize SomatoKine and added allegations of infringement of an additional patent. Insmed
This collaboration will be the second HIV-related collaboration between Benitec and City of Hope. It will be funded through phase I clinical trials by a portion of a
This is the message from new, tougher guidance which has been launched at the Medicines and Healthcare products Regulatory Agency (MHRA)’s first ever seminar on advertising. Speaking about
This approval follows a positive opinion in November 2004 by the European Committee for Medicinal Products for Human Use (CHMP), the human medicines scientific body of the European
The biologics programs are for erythropoietin (EPO), a generic version of Amgen’s Epogen (epoetin-alfa) and granulocyte colony stimulating factor (G-CSF), the generic version of Amgen’s Neupogen (filgrastim). Epogen